Рекомендации по снижениюкардиоваскулярного риска у пациентов с воспалительными артритами(по материалам рекомендаций Европейской антиревматической лиги)

1. <div><p>Sokka T., Abelson B., Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26(Suppl. 51):35-61.</p><p>Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology 2009, doi: 10.1093/rheumatology/kep252</p><p>Avina-Zubieta J.A., Choi H.K., Sadatsafavi M. et al. Risk of Cardiovascular Mortality in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies Arthritis - Rheumatism. Arthritis Care - Research 2008; 59(12):1690-7.</p><p>Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A. et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum 2004;34:585-92. 5.</p><p>Van Halm V.P., Peters M.J., Voskuyl A.E. et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis 2009;68:1395-400.</p><p>Gazi I.F., Boumpas D.T., Mikhailidis D.P. et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatology 2007;25:102-11.</p><p>Насонов Е.Л. Проблема атеротромбоза в ревматологии. Вестн РАМН 2003;7:6-10.</p><p>Montecucco F., Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 2009;48:11-22.</p><p>Peters M.J., Symmons P.M., McCarey D. et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2009;doi: 10.1136/ard.2009.113696.</p><p>Gabriel S.E., Crowson C.S., Kremers H.M. et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8.</p><p>Kvalvik A.G., Jones M.A., Symmons D.P. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scan J Rheumatol 2000;29:29-37.</p><p>Solomon D.H., Goodson N.J., Katz J.N. et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006;65:1608-12.</p><p>Panoulas V.F., Douglas K.M., Milionis H.J. et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007;46:1477-82.</p><p>Solomon D.H., Curhan G.C., Rimm E.B. et al. Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004;50:3444-9.</p><p>Goodson N.J., Silman A.J., Pattison D.J. et al. Traditional cardiovascular risk factors measured prior to the onset of inflammatory polyarthritis. Rheumatology (Oxford) 2004;43:731-6.</p><p>Sattar N., McCarey D.W., Capell H. et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.</p><p>Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.</p><p>Aubry M.C., Maradit-Kremers H., Reinalda M.S. et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007;34:937-42.</p><p>Maradit-Kremers H., Nicola P.J., Crowson C.S. et al. Cardiovascular death in rheumatoid arthritis: a populationbased study. Arthritis Rheum 2005;52:722-32.</p><p>Naranjo A., Sokka T., Descalzo M.A. et al. QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10:30.</p><p>Choi H.K., Hernan M.A., Seeger J.D. et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.</p><p>Wasco M.C., Hubert H., Lingala B. Allcause mortality in RA. Arthritis Rheumatism 2008;58(Suppl. 9):276-81.</p><p>Jacobsson L.T., Turesson C., Gulfe A. et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.</p><p>Dixon W.G., Watson K.D., Lunt M. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.</p><p>Mann D.L., McMurray J.J., Packer M. et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.</p><p>Chung E.S., Packer M., Lo K.H. et al. Randomized, double-blind, placebocontrolled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha, in patients with moderate-tosevere heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.</p><p>Danila M.I., Patkara N.M., Curtisa J.R. et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser- Curr Opin in Rheum 2008;20:327-33.</p><p>Carmona L., Descalzo M.A., PerezPampin E. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5.</p><p>Listing J., Strangfeld A., Kekow J. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis- Arthritis Rheum 2008;58:667-77.</p><p>Оганов Р.Г., Погосова Г.В. Современные стратегии профилактики и лечения сердечно-сосудистых заболеваний. Кардиология 2007;12:4-9.</p><p>Naz S.M., Farragher T.M., Bunn D.K. et al. The influence of age at symptom onset and length of followup on mortality in patients with recent-onset inflammatory polyarthritis. Arthritis Rheum 2008;58:985-9.</p><p>Turesson C., O'Fallon W.M., Crowson C.S. et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.</p><p>Castelli W.P., Garrison R.J., Wilson P.W. et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986;256:2835-8.</p><p>Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994;12:641-7.</p><p>Попкова Т.В., Новикова Д.С., Новиков А.А. и др. Роль воспаления в развитии сердечно-сосудистых осложнений при ревматоидном артрите. Науч-практич ревматол 2009 (прил. к №3):61-8.</p><p>Georgiadis A.N., Papavasiliou E.C., Lourida E.S. et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006;8: R82.</p><p>Popa C., van den Hoogen F.H.J., Radstake T.R.D.J. et al. Modulation of lipоprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007;66:1503-7.</p><p>Peters M.J.L., Vis M., van Halm V.P. et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007;66:958-61.</p><p>Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin. Rheumatology 2005;44:1473-82. 40. Кардиология. Национальное руководство. Под ред. Ю.Н. Беленкова, Р.Г. Оганова. М.: ГЭОТАР-Медиа, 2007;1232 с.</p><p>Flammer A.J., Sudano I., Hermann F. et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008;117:2262-9. 42.</p><p>Европейские рекомендации по профилактике сердечно-сосудистых заболеваний в клинической практике. Рациональная фармакотерапия в кардиологии 2008 (прил. к №3-4):1-40.</p><p>Насонов Е.Л. Перспективы применения статинов в ревматологии. РМЖ 2003;11(23):1273-6.</p><p>Abeles A.M., Pillinger M. Statins as antiinfammatory and immunomodulatory agents. A future in rheumatologic therapy- ArthritisRheumatism 2006;54:393-407.</p><p>Jick S.S., Choi H., Li L. Hyperlipidemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009;68(4):546-51.</p><p>McCarey D.W., McInnes I.B., Madhok R. et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 2004;363:2015-21.</p><p>Shirinsky I.V., Solovyeva N.Y., Zheltova O.I. et al. Efficacy of immunomodulating effects of simvastatin in rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):205.</p><p>Okamoto H., Koizumi K., Kamitsuji S. et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol 2007;34:964-8.</p><p>Edwards C.J., Fisher D., van Staa T. Myocardial infarction in rheumatoid arthritis: the effects of traditional risk factors, antihypertensive and lipid-lowering medication. Arthritis - Rheumatism 2007;58:9:420.</p><p>Kumar P., Khan F., Kennedy G. et al. Effect of rosuvaststin on surrogate markers of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(II):172.</p><p>Petri M., Perez-Gutthann S., Spence D. et al. Lupus Atherosclerosis Prevention Study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 2006;54:5-20.</p><p>Vera-Lastra O., Olvera-Acevedo A., Medina G. Effect of pravastatin plus ezetimibe on carotid intima-media thiknessin patients with systemic lupus erythematosus. Arthritis - Rheumatism 2008;(58):9:330.</p><p>Haag M., Bos M.J., Hofman A. Cyclooxygenase Selectivity of Nonsteroidal Anti-inflammatory Drugs and Risk of Stroke. Arch Intern Med 2008;168(11):1219-24.</p><p>Goodson N.J., Brookhart M.A., Symmons D. et al. Non-Steroidal AntiInflammatory Drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: Results from a primary care based inception cohort of patients. Ann Rheum Dis 2009;68:367-372.</p><p>Solomon D.H., Glynn R.J., Rothman K.J. Subgroup Analyses to Determine Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs and Coxibs in Specific Patient Groups. Arthritis - Rheumatism (Arthritis Care - Research) 2008 August 15;59(8):1097-104.</p><p>Koo B.K., Kim Y.-S., Park K.-W. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREATAXUS trial): an open-label randomised controlled study. Lancet 2007;370:567-74.</p><p>Hayden M., Pignone M., Phillips C. et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-72.</p><p>Mikuls T.R. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17:729-52.</p><p>Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.</p><p>Wolfe F., Michaud K. The Risk of Myocardial Infarction and Pharmacologic and Nonpharmacologic Myocardial Infarction Predictors in Rheumatoid Arthritis A Cohort and Nested Case-Control Analysis. Arthritis - Rheumatism 2008;58(9):2612-21.</p><p>Suissa S., Bernatsky S., Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006;55:531-6.</p><p>Davis J.M., Kremers M.H., Crowson C.S. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a populationbased cohort study. Arthritis Rheum 2007;56:820-30.</p><p>Hafstrom I., Rohani M., Deneberg S. et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis - a randomized study. J Rheumatol 2007;34:1810-6.</p><p>Sihnoven S., Korpela M., Mustonen J. et al. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheum 2006;33:1740-6.</p></div><br />